Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 8/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960776 | 0.79 | MAPT (0.36) | APEX1POLB | |
| SCHEMBL616045 | 0.76 | SLC22A12 (0.39) | APEX1AKR1C3POLBCYP2C9 | |
| SCHEMBL458928 | 0.76 | SLC22A12 (0.39) | APEX1AKR1C3POLBCYP2C9 | |
| SCHEMBL4911340 | 0.74 | HCAR2 (0.44) | HTTCYP2C9EDNRBEDNRA | |
| SCHEMBL9960737 | 0.70 | POLB (0.38) | AKR1C3POLBEDNRBEDNRA | |
| SCHEMBL7764991 | 0.69 | AKR1C3 (0.61) | APEX1AKR1C3RXRARXRBNR4A2 | |
| SCHEMBL7764986 | 0.69 | AKR1C3 (0.61) | APEX1AKR1C3RXRARXRBNR4A2 | |
| SCHEMBL5482288 | 0.68 | POLB (0.46) | APEX1AKR1C3POLBCYP2C9 | |
| SCHEMBL5869639 | 0.68 | POLB (0.46) | APEX1AKR1C3POLBCYP2C9 | |
| SCHEMBL9960738 | 0.67 | POLB (0.35) | POLBEDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | claimed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | claimed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| CN-103443066-A | Ingenol-3-acylates I | LEO LABORATIRIES LTD | 2013-12-11 | — | — | CN | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | APEX1 414/4885AKR1C3 70/4885POLB 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.